The following article is a part of conference coverage from the 2022 American Academy of Dermatology Annual Meeting , held live from March 25 through March 29 in Boston, Massachusetts. The team at Dermatology Advisor will be reporting on the latest news and research conducted by leading experts in dermatology. Check back for more from the 2022 AAD Annual Meeting .

 

Continued treatment over 68 weeks with 2 or 4 mg baricitinib combined with topical corticosteroids was found to be effective among patients with moderate to severe atopic dermatitis (AD), according to study results presented at the 2022 Annual Meeting of the American Academy of Dermatology (AAD), held from March 25 to 29, 2022 in Boston, Massachusetts.


Continue Reading

The BREEZE-AD7 (ClinicalTrials.gov Identifier: NCT03733301) study was a 16-week phase 3 trial of the combinatorial therapy baricitinib with topical corticosteroids for the treatment of moderate to severe AD. Participants who were responders or partial responders to treatment were eligible to participate in the BREEZE-AD3 (ClinicalTrials.gov Identifier: NCT03334435) long-term extension trial.

In the long-term extension, patients remained on the 2 (n=53) or 4 (n=63) mg baricitinib treatment combined with topical corticosteroid regimens, which were assigned during the BREEZE-AD7 trial for 52 additional weeks. The trial endpoints were Validated Investigator Global Assessment for AD (vIGA-AD), Eczema Area and Severity Index-75 (EASI75), and Itch numerical rating scale (NRS) scores.

Among the 2 mg recipients, the proportion of patients achieving vIGA-AD response (vIGA-AD £1) was 39.6% at week 0, 45.3% at week 16, and 30.2% at week 52. EASI75 response was observed among 77.4% of patients at week 0, 69.8% at week 16, and 58.5% at week 52. An itch NRS reduction of 4 points or more was observed among 56.3% of patients at week 0 and 47.9% at week 16.

For the 4 mg recipients, vIGA-AD response was observed among 49.2%, 31.7%, and 34.9% and EASI75 response among 71.4%, 57.1%, and 49.2% at weeks 0, 16, and 52, respectively. There were 53.6% of patients at week 0 and 46.4% at week 16 who achieved an itch NRS reduction of 4 points or higher.

“Baricitinib 4 and 2 mg maintained clinically meaningful long-term efficacy over 68 weeks of continuous treatment in a responder/partial responder population of adult patients with moderate to severe AD,” the study authors noted.

Disclosure: This research was supported by Eli Lilly and Company. Please see the original reference for a full list of disclosures.

Reference

Silverberg JI, Simpson EL, Thyssen JP, et al. Long-term efficacy (to 68 weeks) of baricitinib in adult patients with moderate to severe atopic dermatitis (AD) who were treatment responders or partial responders and originally included in the combination topical corticosteroids study BREEZE-AD7. Presented at: the 2022 AAD Annual Meeting; March 25-29, 2022. Abstract 33233

Visit Dermatology Advisor’s conference section for more coverage from AAD 2022.